Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden in connection with its investment in InDex Pharmaceuticals
Mandate

Vinge advises Industrifonden in connection with its investment in InDex Pharmaceuticals

January 24, 2011

Vinge has advised Industrifonden in connection with its SEK 40 million investment in InDex Pharmaceuticals. InDex Pharmaceuticals develops Kappaproct, a drug developed for the treatment of severe inflammatory bowel disease. Further capital has also been raised from current shareholders, including SEB Venture Capital, which has invested an additional SEK 35 million. The financing will predominantly be used to conduct a clinical phase III trial using Kappaproct with the aim of obtaining market approval.

Vinge’s team consisted of, among others, project manager Johan Larsson and Petter Kjöllerström, who was responsible for the due diligence phase of the transaction. Johan Winnerblad was the responsible partner.

Related

Vinge has advised Ingka Investments on its largest forestland acquisition

 Ingka Investments, the investment arm of Ingka Group (the world’s largest IKEA retailer), has agreed to acquire approximately 153,000 hectares of land, mainly forestland, from Södra, Sweden’s largest forest owners’ association.
October 20, 2025

Vinge advises Procuritas on its acquisition of Parkman

 Vinge has advised Procuritas Capital Investors VII (“Procuritas”) in connection with the acquisition of Parkman i Sverige AB (“Parkman”), a growing Swedish tech-enabled parking operator that provides parking management solutions. As part of the transaction, Indigo Management AS becomes a minority owner of the company.
October 20, 2025

Vinge has advised Eleda in connection with the acquisition of Nordic Infrastructure Group AS (“Qben Rail”)

 Qben Infra AB and ININ Group AS, which is majority owned by Qben Infra AB, have entered into a share purchase agreement with Eleda through Eleda’s subsidiary Eleda Norge AS (“Eleda”), to divest the Qben Rail platform to Eleda for a total enterprise value of up to NOK 850 million, including an earn out of up to NOK 65 million. Completion of the transaction is subject to customary closing conditions, including approval from the Swedish Inspectorate of Strategic Products and the Norwegian Competition Authority.
October 17, 2025